Floatz logo

Lapatinib

GBM

National Cancer Institute (NCI)Small moleculePhase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the GBM cohort.

Asset / SponsorPhaseRating
LENVATINIB
Tel Aviv Medical Center
Phase 2BB
CHLOROTOXIN
TransMolecular
Phase 2BB
FET
Thomas Hope
Phase 2B
MANNITOL
Northwell Health
Phase 2B
Silevertinib
Black Diamond Therapeutics, Inc.
Phase 2B

View all 18 →

Same molecule, other indications

Lapatinib is also rated in:

breast cancerDormant
BBB
Indicative ·
76 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
male breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →